The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

A spokesperson for Owkin explained how their work will be carried out, in practice: “We are using AI to predict tumour evolution based on histology slides (over 1,000 tissue samples from 100 ...